Venous Thromboembolic Disease

Restricted access
  • 1

    Khorana AA, Francis CW, Culakova E. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484-490.

  • 2

    Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost 2002;87:575-579.

    • Search Google Scholar
    • Export Citation
  • 3

    Heit JA O'Fallon WM, Petterson TM. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002;162:1245-1248.

    • Search Google Scholar
    • Export Citation
  • 4

    Monreal M, Fernandez-Llamazares J, Perandreu J. Occult cancer in patients with venous thromboembolism: which patients, which cancers. Thromb Haemost 1997;78:1316-1318.

    • Search Google Scholar
    • Export Citation
  • 5

    Bick RL. Cancer-associated thrombosis: focus on extended therapy with dalteparin. J Support Oncol 2006;4:115-120.

  • 6

    Lopez JA, Kearon C, Lee AY. Deep venous thrombosis. Hematology Am Soc Hematol Educ Program 2004:439-456.

  • 7

    Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica 1999;84:437-445.

  • 8

    Otten HM, Mathijssen J, ten Cate H. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 2004;164:190-194.

    • Search Google Scholar
    • Export Citation
  • 9

    Chew HK, Wun T, Harvey D. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 2006;166:458-464.

    • Search Google Scholar
    • Export Citation
  • 10

    Chew HK, Wun T, Harvey DJ. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 2007;25:70-76.

    • Search Google Scholar
    • Export Citation
  • 11

    Kuderer NM, Francis CW, Culakova E. Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy [abstract]. J Clin Oncol 2008;26(Suppl 15):Abstract 9521.

    • Search Google Scholar
    • Export Citation
  • 12

    Martino MA, Williamson E, Siegfried S. Diagnosing pulmonary embolism: experience with spiral CT pulmonary angiography in gynecologic oncology. Gynecol Oncol 2005;98:289-293.

    • Search Google Scholar
    • Export Citation
  • 13

    Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-1850.

  • 14

    Agnelli G, Bolis G, Capussotti L. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 2006;243:89-95.

    • Search Google Scholar
    • Export Citation
  • 15

    Kakkar AK, Levine M, Pinedo HM. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist 2003;8:381-388.

  • 16

    Cohen AT, Tapson VF, Bergmann JF. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008;371:387-394.

    • Search Google Scholar
    • Export Citation
  • 17

    Tapson VF, Decousus H, Pini M. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 2007;132:936-945.

    • Search Google Scholar
    • Export Citation
  • 18

    Alikhan R, Peters F, Wilmott R, Cohen AT. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol 2004;57:1254-1257.

  • 19

    Cohen AT, Alikhan R, Arcelus JI. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 2005;94:750-759.

    • Search Google Scholar
    • Export Citation
  • 20

    Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009;27:4839-4847.

  • 21

    Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010;125(Suppl 2):1-7.

    • Search Google Scholar
    • Export Citation
  • 22

    Ageno W, Squizzato A, Garcia D, Imberti D. Epidemiology and risk factors of venous thromboembolism. Semin Thromb Hemost 2006;32:651-658.

  • 23

    Hicks LK, Cheung MC, Ding K. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Trials Group trials. Cancer 2009;115:5516-5525.

    • Search Google Scholar
    • Export Citation
  • 24

    Khorana AA, Kuderer NM, Culakova E. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111:4902-4907.

    • Search Google Scholar
    • Export Citation
  • 25

    Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104:2822-2829.

    • Search Google Scholar
    • Export Citation
  • 26

    Mandalà M, Barni S, Prins M. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol 2010;21:871-876.

    • Search Google Scholar
    • Export Citation
  • 27

    Darze ES, Latado AL, Guimaraes AG. Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest 2005;128:2576-2580.

    • Search Google Scholar
    • Export Citation
  • 28

    Kroger K, Weiland D, Ose C. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006;17:297-303.

  • 29

    Prandoni P, Lensing AW, Prins MH. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955-960.

    • Search Google Scholar
    • Export Citation
  • 30

    Prandoni P, Lensing AW, Piccioli A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-3488.

    • Search Google Scholar
    • Export Citation
  • 31

    Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-722.

  • 32

    Heit JA, Silverstein MD, Mohr DN. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000;160:809-815.

    • Search Google Scholar
    • Export Citation
  • 33

    Ogren M, Bergqvist D, Wahlander K. Trousseau's syndrome–what is the evidence? A population-based autopsy study. Thromb Haemost 2006;95:541-545.

    • Search Google Scholar
    • Export Citation
  • 34

    Hall IE, Andersen MS, Krumholz HM, Gross CP. Predictors of venous thromboembolism in patients with advanced common solid cancers. J Cancer Epidemiol 2009:182521.

    • Search Google Scholar
    • Export Citation
  • 35

    Sandhu R, Pan C-X, Wun T. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer 2010;116:2596-2603.

    • Search Google Scholar
    • Export Citation
  • 36

    Levitan N, Dowlati A, Remick SC. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-291.

    • Search Google Scholar
    • Export Citation
  • 37

    Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006;24:1310-1318.

    • Search Google Scholar
    • Export Citation
  • 38

    Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation 2003;107:17-21.

  • 39

    Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000;89:640-646.

    • Search Google Scholar
    • Export Citation
  • 40

    Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009;27:4848-4857.

  • 41

    Palumbo A, Rajkumar SV, Dimopoulos MA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-423.

  • 42

    Ottinger H, Belka C, Kozole G. Deep venous thrombosis and pulmonary artery embolism in high-grade non Hodgkin's lymphoma: incidence, causes and prognostic relevance. Eur J Haematol 1995;54:186-194.

    • Search Google Scholar
    • Export Citation
  • 43

    Andtbacka RHI, Babiera G, Singletary SE. Incidence and prevention of venous thromboembolism in patients undergoing breast cancer surgery and treated according to clinical pathways. Ann Surg 2006;243:96-101.

    • Search Google Scholar
    • Export Citation
  • 44

    Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006;118:555-568.

  • 45

    Ay C, Dunkler D, Marosi C. Prediction of venous thromboembolism in cancer patients. Blood 2010;116:5377-5382.

  • 46

    Cummings SR, Eckert S, Krueger KA. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.

    • Search Google Scholar
    • Export Citation
  • 47

    Decensi A, Maisonneuve P, Rotmensz N. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005;111:650-656.

    • Search Google Scholar
    • Export Citation
  • 48

    Fisher B, Costantino JP, Wickerham DL. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-1662.

    • Search Google Scholar
    • Export Citation
  • Fisher B, Costantino JP, Wickerham DL. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.

    • Search Google Scholar
    • Export Citation
  • 50

    Vogel VG, Costantino JP, Wickerham DL. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696-706.

    • Search Google Scholar
    • Export Citation
  • 51

    Anderson GL, Limacher M, Assaf AR. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.

    • Search Google Scholar
    • Export Citation
  • 52

    Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.

    • Search Google Scholar
    • Export Citation
  • 53

    Blanco-Molina A, Trujillo-Santos J, Tirado R. Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE registry. Thromb Haemost 2009;101:478-482.

    • Search Google Scholar
    • Export Citation
  • 54

    Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004;164:1965-1976.

    • Search Google Scholar
    • Export Citation
  • 55

    Leaf AN, Propert K, Corcoran C. Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study. Med Oncol 2003;20:137-146.

    • Search Google Scholar
    • Export Citation
  • 56

    Bennett CL, Angelotta C, Yarnold PR. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006;296:2558-2560.

    • Search Google Scholar
    • Export Citation
  • 57

    El Accaoui RN, Shamseddeen WA, Taher AT. Thalidomide and thrombosis. A meta-analysis. Thromb Haemost 2007;97:1031-1036.

  • 58

    Hussein MA. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 2006;95:924-930.

    • Search Google Scholar
    • Export Citation
  • 59

    Knight R, DeLap RJ, Zeldis JB. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006;354:2079-2080.

  • 60

    Weber DM, Chen C, Niesvizky R. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142.

    • Search Google Scholar
    • Export Citation
  • 61

    Zangari M, Siegel E, Barlogie B. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100:1168-1171.

    • Search Google Scholar
    • Export Citation
  • 62

    Nalluri SR, Chu D, Keresztes R. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300:2277-2285.

    • Search Google Scholar
    • Export Citation
  • 63

    Bennett CL, Silver SM, Djulbegovic B. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.

    • Search Google Scholar
    • Export Citation
  • 64

    Baarslag HJ, Koopman MM, Hutten BA. Long-term follow-up of patients with suspected deep vein thrombosis of the upper extremity: survival, risk factors and post-thrombotic syndrome. Eur J Intern Med 2004;15:503-507.

    • Search Google Scholar
    • Export Citation
  • 65

    Prandoni P, Polistena P, Bernardi E. Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med 1997;157:57-62.

    • Search Google Scholar
    • Export Citation
  • 66

    Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:3665-3675.

    • Search Google Scholar
    • Export Citation
  • 67

    Lee AY, Levine MN, Butler G. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006;24:1404-1408.

    • Search Google Scholar
    • Export Citation
  • 68

    Joffe HV, Goldhaber SZ. Upper-extremity deep vein thrombosis. Circulation 2002;106:1874-1880.

  • 69

    Linenberger ML. Catheter-related thrombosis: risks, diagnosis, and management. J Natl Compr Canc Netw 2006;4:889-901.

  • 70

    van Rooden CJ, Schippers EF, Barge RM. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005;23:2655-2660.

    • Search Google Scholar
    • Export Citation
  • 71

    Kearon C, Ginsberg JS, Douketis J. An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med 2006;144:812-821.

    • Search Google Scholar
    • Export Citation
  • 72

    Wells PS, Anderson DR, Rodger M. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003;349:1227-1235.

  • 73

    Sohne M, Kruip MJ, Nijkeuter M. Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. J Thromb Haemost 2006;4:1042-1046.

    • Search Google Scholar
    • Export Citation
  • 74

    Knowlson L, Bacchu S, Paneesha S. Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism. J Clin Pathol 2010;63:818-822.

    • Search Google Scholar
    • Export Citation
  • 75

    Agnelli G, Verso M, Ageno W. The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Res 2008;121:605-610.

  • 76

    Zierler BK. Ultrasonography and diagnosis of venous thromboembolism. Circulation 2004;109:I9-14.

  • 77

    Birdwell BG, Raskob GE, Whitsett TL. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med 1998;128:1-7.

    • Search Google Scholar
    • Export Citation
  • 78

    Kanne JP, Lalani TA. Role of computed tomography and magnetic resonance imaging for deep venous thrombosis and pulmonary embolism. Circulation 2004;109:15-21.

    • Search Google Scholar
    • Export Citation
  • 79

    Lim KE, Hsu WC, Hsu YY. Deep venous thrombosis: comparison of indirect multidetector CT venography and sonography of lower extremities in 26 patients. Clin Imaging 2004;28:439-444.

    • Search Google Scholar
    • Export Citation
  • 80

    Male C, Chait P, Ginsberg JS. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost 2002;87:593-598.

    • Search Google Scholar
    • Export Citation
  • 81

    Segal JB, Eng J, Jenckes MW. Diagnosis and treatment of deep venous thrombosis and pulmonary embolism. Evid Rep Technol Assess (Summ) 2003:1-6.

    • Search Google Scholar
    • Export Citation
  • 82

    Gaitini D. Current approaches and controversial issues in the diagnosis of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound 2006;34:289-297.

    • Search Google Scholar
    • Export Citation
  • 83

    Taffoni MJ, Ravenel JG, Ackerman SJ. Prospective comparison of indirect CT venography versus venous sonography in ICU patients. AJR Am J Roentgenol 2005;185:457-462.

    • Search Google Scholar
    • Export Citation
  • 84

    Fraser DG, Moody AR, Davidson IR. Deep venous thrombosis: diagnosis by using venous enhanced subtracted peak arterial MR venography versus conventional venography. Radiology 2003;226:812-820.

    • Search Google Scholar
    • Export Citation
  • 85

    Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol 2007;17:175-181.

    • Search Google Scholar
    • Export Citation
  • 86

    Joffe HV, Kucher N, Tapson VF, Goldhaber SZ. Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation 2004;110:1605-1611.

    • Search Google Scholar
    • Export Citation
  • 87

    Baarslag HJ, van Beek EJ, Koopman MM, Reekers JA. Prospective study of color duplex ultrasonography compared with contrast venography in patients suspected of having deep venous thrombosis of the upper extremities. Ann Intern Med 2002;136:865-872.

    • Search Google Scholar
    • Export Citation
  • 88

    Decousus H, Quere I, Presles E. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med 2010;152:218-224.

    • Search Google Scholar
    • Export Citation
  • 89

    Lee JT, Kalani MA. Treating superficial venous thrombophlebitis. J Natl Compr Canc Netw 2008;6:760-765.

  • 90

    Sack GH, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977;56:1-37.

    • Search Google Scholar
    • Export Citation
  • 91

    Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007;110:1723-1729.

  • 92

    Martinelli I, Franchini M, Mannucci PM. How I treat rare venous thromboses. Blood 2008;112:4818-4823.

  • 93

    Thatipelli MR, McBane RD, Hodge DO, Wysokinski WE. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol 2010;8:200-205.

    • Search Google Scholar
    • Export Citation
  • 94

    Amitrano L, Guardascione MA, Scaglione M. Prognostic factors in noncirrhotic patients with splanchnic vein thromboses. Am J Gastroenterol 2007;102:2464-2470.

    • Search Google Scholar
    • Export Citation
  • 95

    Janssen HL, Wijnhoud A, Haagsma EB. Extrahepatic portal vein thrombosis: etiology and determinants of survival. Gut 2001;49:720-724.

  • 96

    Acosta S, Alhadad A, Svensson P, Ekberg O. Epidemiology, risk and prognostic factors in mesenteric venous thrombosis. Br J Surg 2008;95:1245-1251.

    • Search Google Scholar
    • Export Citation
  • 97

    Hedayati N, Riha GM, Kougias P. Prognostic factors and treatment outcome in mesenteric vein thrombosis. Vasc Endovascular Surg 2008;42:217-224.

    • Search Google Scholar
    • Export Citation
  • 98

    De Stefano V, Martinelli I. Splanchnic vein thrombosis: clinical presentation, risk factors and treatment. Intern Emerg Med 2010;5:487-494.

  • 99

    Janssen HL, Meinardi JR, Vleggaar FP. Factor V leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000;96:2364-2368.

    • Search Google Scholar
    • Export Citation
  • 100

    Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med 2001;345:1683-1688.

  • 101

    Connolly GC, Chen R, Hyrien O. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res 2008;122:299-306.

    • Search Google Scholar
    • Export Citation
  • 102

    Greten TF, Papendorf F, Bleck JS. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005;92:1862-1868.

    • Search Google Scholar
    • Export Citation
  • 103

    Rabe C, Pilz T, Klostermann C. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma. World J Gastroenterol 2001;7:208-215.

    • Search Google Scholar
    • Export Citation
  • 104

    Cabibbo G, Enea M, Attanasio M. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274-1283.

    • Search Google Scholar
    • Export Citation
  • 105

    Hoekstra J, Janssen HL. Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome. Neth J Med 2008;66:334-339.

    • Search Google Scholar
    • Export Citation
  • 106

    Hoekstra J, Janssen HL. Vascular liver disorders (II): portal vein thrombosis. Neth J Med 2009;67:46-53.

  • 107

    Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med 2004;350:578-585.

  • 108

    Parikh S, Shah R, Kapoor P. Portal vein thrombosis. Am J Med 2010;123:111-119.

  • 109

    Plessier A, Darwish-Murad S, Hernandez-Guerra M. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010;51:210-218.

    • Search Google Scholar
    • Export Citation
  • 110

    Sogaard KK, Astrup LB, Vilstrup H, Gronbaek H. Portal vein thrombosis; risk factors, clinical presentation and treatment. BMC Gastroenterol 2007;7:34.

    • Search Google Scholar
    • Export Citation
  • 111

    Bradbury MS, Kavanagh PV, Bechtold RE. Mesenteric venous thrombosis: diagnosis and noninvasive imaging. Radiographics 2002;22:527-541.

  • 112

    Ponziani FR, Zocco MA, Campanale C. Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment. World J Gastroenterol 2010;16:143-155.

    • Search Google Scholar
    • Export Citation
  • 113

    Hillmen P, Lewis SM, Bessler M. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:1253-1258.

  • 114

    Socie G, Mary JY, de Gramont A. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996;348:573-577.

    • Search Google Scholar
    • Export Citation
  • 115

    Hoekstra J, Leebeek FW, Plessier A. Paroxysmal nocturnal hemoglobinuria in Budd-Chiari syndrome: findings from a cohort study. J Hepatol 2009;51:696-706.

    • Search Google Scholar
    • Export Citation
  • 116

    Baxter EJ, Scott LM, Campbell PJ. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.

    • Search Google Scholar
    • Export Citation
  • 117

    James C, Ugo V, Le Couedic JP. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148.

    • Search Google Scholar
    • Export Citation
  • 118

    Kralovics R, Passamonti F, Buser AS. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.

  • 119

    Levine RL, Wadleigh M, Cools J. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.

    • Search Google Scholar
    • Export Citation
  • 120

    Colaizzo D, Amitrano L, Tiscia GL. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007;5:55-61.

    • Search Google Scholar
    • Export Citation
  • 121

    De Stefano V, Fiorini A, Rossi E. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007;5:708-714.

    • Search Google Scholar
    • Export Citation
  • 122

    Regina S, Herault O, D'Alteroche L. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007;5:859-861.

    • Search Google Scholar
    • Export Citation
  • 123

    Colaizzo D, Amitrano L, Tiscia GL. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 2007;110:2768-2769.

    • Search Google Scholar
    • Export Citation
  • 124

    Fanikos J, Goldhaber SZ. Risk factors for the assessment of patients with pulmonary embolism. J Natl Compr Canc Netw 2006;4:871-880.

  • 125

    Kearon C, Ginsberg JS, Hirsh J. The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med 1998;129:1044-1049.

    • Search Google Scholar
    • Export Citation
  • 126

    Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994;271:223-225.

    • Search Google Scholar
    • Export Citation
  • 127

    O'Connell CL, Boswell WD, Duddalwar V. Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol 2006;24:4928-4932.

    • Search Google Scholar
    • Export Citation
  • 128

    Worsley DF, Alavi A, Aronchick JM. Chest radiographic findings in patients with acute pulmonary embolism: observations from the PIOPED Study. Radiology 1993;189:133-136.

    • Search Google Scholar
    • Export Citation
  • 129

    Costantini M, Bossone E, Renna R. Electrocardiographic features in critical pulmonary embolism. Results from baseline and continuous electrocardiographic monitoring. Ital Heart J 2004;5:214-216.

    • Search Google Scholar
    • Export Citation
  • 130

    Ferrari E, Imbert A, Chevalier T. The ECG in pulmonary embolism. Predictive value of negative T waves in precordial leads–80 case reports. Chest 1997;111:537-543.

    • Search Google Scholar
    • Export Citation
  • 131

    Schoepf UJ, Costello P. CT angiography for diagnosis of pulmonary embolism: state of the art. Radiology 2004;230:329-337.

  • 132

    Czekajska-Chehab E, Drop A, Terlecka B. Indirect CT venography of the abdominal cavity and lower limbs in patients with the suspicion of pulmonary embolism–indications, technique, diagnostic possibilities. Ann Univ Mariae Curie Sklodowska Med 2004;59:508-518.

    • Search Google Scholar
    • Export Citation
  • 133

    Schoepf UJ, Kucher N, Kipfmueller F. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 2004;110:3276-3280.

    • Search Google Scholar
    • Export Citation
  • 134

    Anderson DR, Kahn SR, Rodger MA. Computed tomographic pulmonary angiography vs ventilation-perfusion lung scanning in patients with suspected pulmonary embolism: a randomized controlled trial. JAMA 2007;298:2743-2753.

    • Search Google Scholar
    • Export Citation
  • 135

    Calvo-Romero JM, Lima-Rodriguez EM, Bureo-Dacal P, Perez-Miranda M. Predictors of an intermediate ventilation/perfusion lung scan in patients with suspected acute pulmonary embolism. Eur J Emerg Med 2005;12:129-131.

    • Search Google Scholar
    • Export Citation
  • 136

    Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-1389.

    • Search Google Scholar
    • Export Citation
  • 137

    Jimenez D, Aujesky D, Moores L. Combinations of prognostic tools for identification of high-risk normotensive patients with acute symptomatic pulmonary embolism. Thorax 2011;66:75-81.

    • Search Google Scholar
    • Export Citation
  • 138

    Jimenez D, Aujesky D, Yusen RD. Risk stratification of normotensive patients with acute symptomatic pulmonary embolism. Br J Haematol 2010;151:415-424.

    • Search Google Scholar
    • Export Citation
  • 139

    Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation 2003;108:2191-2194.

    • Search Google Scholar
    • Export Citation
  • 140

    Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. Circulation 2005;112:e28-32.

  • 141

    Pruszczyk P, Torbicki A, Kuch-Wocial A. Diagnostic value of transoesophageal echocardiography in suspected haemodynamically significant pulmonary embolism. Heart 2001;85:628-634.

    • Search Google Scholar
    • Export Citation
  • 142

    Ribeiro A, Lindmarker P, Juhlin-Dannfelt A. Echocardiography doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997;134:479-487.

    • Search Google Scholar
    • Export Citation
  • 143

    Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007;116:427-433.

  • 144

    Konstantinides S, Geibel A, Olschewski M. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002;106:1263-1268.

    • Search Google Scholar
    • Export Citation
  • 145

    Jimenez D, Aujesky D, Diaz G. Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2010;181:983-991.

    • Search Google Scholar
    • Export Citation
  • 146

    Aujesky D, Roy PM, Le Manach CP. Validation of a model to predict adverse outcomes in patients with pulmonary embolism. Eur Heart J 2006;27:476-481.

    • Search Google Scholar
    • Export Citation
  • 147

    Donze J, Le Gal G, Fine MJ. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost 2008;100:943-948.

    • Search Google Scholar
    • Export Citation
  • 148

    LEO Pharmaceutical Products. Prescribing information: Innohep (tinzaparin sodium injection) for subcutaneous (SC) use only. 2008. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020484s011lbl.pdf. Accessed February 18, 2011.

    • Search Google Scholar
    • Export Citation
  • 149

    sanofi-aventis U.S. LLC. Prescribing information: Lovenox (enoxaparin sodium injection). 2009. Available at: http://products.sanofi-aventis.us/lovenox/lovenox.html. Accessed February 18, 2011.

    • Search Google Scholar
    • Export Citation
  • 150

    GlaxoSmithKline. Prescribing information: ARIXTRA (fondaparinux sodium) Solution for subcutaneous injection. 2010. Available at: http://us.gsk.com/products/assets/us_arixtra.pdf. Accessed February 18, 2011.

    • Search Google Scholar
    • Export Citation
  • 151

    Eisai, Inc; Pfizer, Inc. Prescribing information: FRAGMIN (dalteparin sodium injection) for Subcutaneous Use Only. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020287s050lbl.pdf. Accessed March 2, 2011.

    • Search Google Scholar
    • Export Citation
  • 152

    Hospira, Inc. Prescribing information: Heparin sodium injection, USP. 2008. Available at: http://www.hospira.com/Files/heparin_sodium_injection.pdf. Accessed February 18, 2011.

    • Search Google Scholar
    • Export Citation
  • 153

    Cervera R, Khamashta MA, Shoenfeld Y. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009;68:1428-1432.

    • Search Google Scholar
    • Export Citation
  • 154

    Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 2006;295:1050-1057.

  • 155

    Lim W. Antiphospholipid antibody syndrome. Hematology Am Soc Hematol Educ Program 2009:233-239.

  • 156

    Hutten BA, Prins MH, Gent M. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000;18:3078-3083.

    • Search Google Scholar
    • Export Citation
  • 157

    Palareti G, Legnani C, Lee A. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-810.

    • Search Google Scholar
    • Export Citation
  • 158

    Hull RD, Pineo GF, Brant RF. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-1072.

    • Search Google Scholar
    • Export Citation
  • 159

    Lee AY, Levine MN, Baker RI. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-153.

    • Search Google Scholar
    • Export Citation
  • 160

    Meyer G, Marjanovic Z, Valcke J. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-1735.

    • Search Google Scholar
    • Export Citation
  • 161

    Wawrzynska L, Tomkowski WZ, Przedlacki J. Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb 2003;33:64-67.

    • Search Google Scholar
    • Export Citation
  • 162

    Aronson J. Serious drug interactions. Practitioner 1993;237:789-791.

  • 163

    Lacey CS. Interaction of dicloxacillin with warfarin. Ann Pharmacother 2004;38:898.

  • 164

    Saif MW. An adverse interaction between warfarin and fluoropyrimidines revisited. Clin Colorectal Cancer 2005;5:175-180.

  • 165

    Shah HR, Ledbetter L, Diasio R, Saif MW. A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer 2006;5:354-358.

    • Search Google Scholar
    • Export Citation
  • 166

    Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003;42:361-372.

  • 167

    Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 2006;5:433-451.

    • Search Google Scholar
    • Export Citation
  • 168

    Sconce E, Khan T, Mason J. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost 2005;93:872-875.

    • Search Google Scholar
    • Export Citation
  • 169

    Wittkowsky AK, Boccuzzi SJ, Wogen J. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 2004;24:1668-1674.

    • Search Google Scholar
    • Export Citation
  • 170

    Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960;1:1309-1312.

  • 171

    Hirsh J, Bates SM. Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective. Ann Intern Med 2001;134:409-417.

    • Search Google Scholar
    • Export Citation
  • 172

    Geerts WH, Bergqvist D, Pineo GF. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(Suppl 6):381S-453S.

    • Search Google Scholar
    • Export Citation
  • 173

    Kearon C, Kahn SR, Agnelli G. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(Suppl 6):454S-545S.

    • Search Google Scholar
    • Export Citation
  • 174

    Wells PS, Anderson DR, Rodger MA. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005;165:733-738.

    • Search Google Scholar
    • Export Citation
  • 175

    Cheer SM, Dunn CJ, Foster R. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease. Drugs 2004;64:1479-1502.

    • Search Google Scholar
    • Export Citation
  • 176

    Neely JL, Carlson SS, Lenhart SE. Tinzaparin sodium: a low-molecular-weight heparin. Am J Health Syst Pharm 2002;59:1426-1436.

  • 177

    Nutescu EA, Shapiro NL, Feinstein H, Rivers CW. Tinzaparin: considerations for use in clinical practice. Ann Pharmacother 2003;37:1831-1840.

  • 178

    Planes A, Samama MM, Lensing AW. Prevention of deep vein thrombosis after hip replacement–comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost 1999;81:22-25.

    • Search Google Scholar
    • Export Citation
  • 179

    Mandalà M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 2008;19(Suppl 2):126-127.

    • Search Google Scholar
    • Export Citation
  • 180

    Cook LM, Kahn SR, Goodwin J, Kovacs MJ. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost 2007;5:937-941.

    • Search Google Scholar
    • Export Citation
  • 181

    Hirsh J, Bauer KA, Donati MB. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(Suppl 6):141S-159S.

    • Search Google Scholar
    • Export Citation
  • 182

    Michota F, Merli G. Anticoagulation in special patient populations: are special dosing considerations required? Cleve Clin J Med 2005;72(Suppl 1):S37-42.

    • Search Google Scholar
    • Export Citation
  • 183

    Sanderink GJ, Guimart CG, Ozoux ML. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225-231.

    • Search Google Scholar
    • Export Citation
  • 184

    Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006;144:673-684.

    • Search Google Scholar
    • Export Citation
  • 185

    Hulot JS, Montalescot G, Lechat P. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005;77:542-552.

    • Search Google Scholar
    • Export Citation
  • 186

    Kruse MW, Lee JJ. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment. Am Heart J 2004;148:582-589.

    • Search Google Scholar
    • Export Citation
  • 187

    Shprecher AR, Cheng-Lai A, Madsen EM. Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls. Pharmacotherapy 2005;25:817-822.

    • Search Google Scholar
    • Export Citation
  • 188

    Douketis J, Cook D, Meade M. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med 2008;168:1805-1812.

    • Search Google Scholar
    • Export Citation
  • 189

    Mahe I, Aghassarian M, Drouet L. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007;97:581-586.

    • Search Google Scholar
    • Export Citation
  • 190

    Pautas E, Gouin I, Bellot O. Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients. Drug Saf 2002;25:725-733.

    • Search Google Scholar
    • Export Citation
  • 191

    Siguret V, Pautas E, Fevrier M. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000;84:800-804.

    • Search Google Scholar
    • Export Citation
  • 192

    Leizorovicz A. Tinzaparin compared to unfractionated heparin for initial treatment of deep vein thrombosis in very elderly patients with renal insufficiency–the IRIS trial [abstract]. Blood 2008;112:Abstract 434.

    • Search Google Scholar
    • Export Citation
  • 193

    Kucher N, Leizorovicz A, Vaitkus PT. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 2005;165:341-345.

    • Search Google Scholar
    • Export Citation
  • 194

    Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 2005;106:4027-4033.

  • 195

    Savi P, Chong BH, Greinacher A. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005;105:139-144.

    • Search Google Scholar
    • Export Citation
  • 196

    Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(Suppl 6):340S-380S.

    • Search Google Scholar
    • Export Citation
  • 197

    Cohen AT, Davidson BL, Gallus AS. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006;332:325-329.

    • Search Google Scholar
    • Export Citation
  • 198

    Hirsh J, Anand SS, Halperin JL, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. Arterioscler Thromb Vasc Biol 2001;21:1094-1096.

    • Search Google Scholar
    • Export Citation
  • 199

    Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988;208:227-240.

    • Search Google Scholar
    • Export Citation
  • 200

    King CS, Holley AB, Jackson JL. Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population: a metaanalysis. Chest 2007;131:507-516.

    • Search Google Scholar
    • Export Citation
  • 201

    Kearon C, Ginsberg JS, Julian JA. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006;296:935-942.

    • Search Google Scholar
    • Export Citation
  • 202

    Bristol-Myers Squibb. Prescribing information: COUMADIN® TABLETS (Warfarin Sodium Tablets, USP); COUMADIN® FOR INJECTION (Warfarin Sodium for Injection, USP). 2010. Available at: http://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed February 18, 2011.

    • Search Google Scholar
    • Export Citation
  • 203

    Glynn RJ, Ridker PM, Goldhaber SZ, Buring JE. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med 2007;147:525-533.

    • Search Google Scholar
    • Export Citation
  • 204

    Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation 2005;112:416-422.

    • Search Google Scholar
    • Export Citation
  • 205

    Brender E. Use of emboli-blocking filters increases, but rigorous data are lacking. JAMA 2006;295:989-990.

  • 206

    Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 2004;164:1541-1545.

  • 207

    Streiff MB. Vena caval filters: a comprehensive review. Blood 2000;95:3669-3677.

  • 208

    Streiff MB. Vena caval filters: a review for intensive care specialists. J Intensive Care Med 2003;18:59-79.

  • 209

    Decousus H, Leizorovicz A, Parent F. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409-415.

    • Search Google Scholar
    • Export Citation
  • 210

    Elting LS, Escalante CP, Cooksley C. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004;164:1653-1661.

    • Search Google Scholar
    • Export Citation
  • 211

    Getzen TM, Rectenwald JE. Inferior vena cava filters in the cancer patient: current use and indications. J Natl Compr Canc Netw 2006;4:881-888.

    • Search Google Scholar
    • Export Citation
  • 212

    Millward SF, Grassi CJ, Kinney TB. Reporting standards for inferior vena caval filter placement and patient follow-up: supplement for temporary and retrievable/optional filters. J Vasc Interv Radiol 2005;16:441-443.

    • Search Google Scholar
    • Export Citation
  • 213

    Kim HS, Young MJ, Narayan AK. A comparison of clinical outcomes with retrievable and permanent inferior vena cava filters. J Vasc Interv Radiol 2008;19:393-399.

    • Search Google Scholar
    • Export Citation
  • 214

    Nicholson W, Nicholson WJ, Tolerico P. Prevalence of fracture and fragment embolization of Bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade. Arch Intern Med 2010;170:1827-1831.

    • Search Google Scholar
    • Export Citation
  • 215

    Francis CW. Prevention of venous thromboembolism in hospitalized patients with cancer. J Clin Oncol 2009;27:4874-4880.

  • 216

    Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 1997;84:1099-1103.

    • Search Google Scholar
    • Export Citation
  • 217

    Mismetti P, Laporte S, Darmon JY. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001;88:913-930.

    • Search Google Scholar
    • Export Citation
  • 218

    DeBernardo RL, Perkins RB, Littell RD. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. Obstet Gynecol 2005;105:1006-1011.

    • Search Google Scholar
    • Export Citation
  • 219

    Akl EA, Terrenato I, Barba M. Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med 2008;168:1261-1269.

    • Search Google Scholar
    • Export Citation
  • 220

    Couban S, Goodyear M, Burnell M. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol 2005;23:4063-4069.

    • Search Google Scholar
    • Export Citation
  • 221

    Karthaus M, Kretzschmar A, Kroning H. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol 2006;17:289-296.

    • Search Google Scholar
    • Export Citation
  • 222

    Verso M, Agnelli G, Bertoglio S. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol 2005;23:4057-4062.

    • Search Google Scholar
    • Export Citation
  • 223

    Young AM, Billingham LJ, Begum G. Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial. Lancet 2009;373:567-574.

    • Search Google Scholar
    • Export Citation
  • 224

    Martino MA, Borges E, Williamson E. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol 2006;107:666-671.

  • 225

    Bergqvist D, Agnelli G, Cohen AT. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-980.

    • Search Google Scholar
    • Export Citation
  • 226

    Rasmussen MS, Jorgensen LN, Wille-Jorgensen P. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: a multicenter randomized open-label study. J Thromb Haemost 2006;4:2384-2390.

    • Search Google Scholar
    • Export Citation
  • 227

    Rana P, Levine MN. Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol 2009;27:4885-4888.

  • 228

    Zangari M, Fink LM, Elice F. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009;27:4865-4873.

  • 229

    Celgene Corporation. Prescribing information: REVLIMID (lenalidomide) capsules. 2010. Available at: http://www.revlimid.com/pdf/REVLIMID_PI.pdf. Accessed February 18, 2011.

    • Search Google Scholar
    • Export Citation
  • 230

    Celgene Corporation. Prescribing information: THALOMID® (thalidomide) Capsules 50 mg, 100 mg, 150 mg & 200 mg. 2010. Available at: http://www.thalomid.com/pdf/Thalomid%20PI%2072991-10.pdf. Accessed February 18, 2011.

    • Search Google Scholar
    • Export Citation
  • 231

    Palumbo A, Cavo M, Bringhen S. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide:a phase III, open-label, randomized trial. J Clin Oncol 2011;29:986-993.

    • Search Google Scholar
    • Export Citation
  • 232

    Agnelli G, Gussoni G, Bianchini C. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009;10:943-949.

    • Search Google Scholar
    • Export Citation
  • 233

    Riess H, Pelzer U, Opitz B. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: final results of the CONKO-004 trial [abstract]. J Clin Oncol 2010;28(Suppl 15):Abstract 4033.

    • Search Google Scholar
    • Export Citation
  • 234

    Cohen AT, Nandini B, Wills JO, Ota S. VTE prophylaxis for the medical patient: where do we stand?–a focus on cancer patients. Thromb Res 2010;125(Suppl 2):S21-29.

    • Search Google Scholar
    • Export Citation
  • 235

    Clarke-Pearson DL, Synan IS, Dodge R. A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. Am J Obstet Gynecol 1993;168:1146-1153.

    • Search Google Scholar
    • Export Citation
  • 236

    Ramirez JI, Vassiliu P, Gonzalez-Ruiz C. Sequential compression devices as prophylaxis for venous thromboembolism in high-risk colorectal surgery patients: reconsidering American Society of Colorectal Surgeons parameters. Am Surg 2003;69:941-945.

    • Search Google Scholar
    • Export Citation
  • 237

    Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 2000;3:CD001484.

  • 238

    Cohen AT, Skinner JA, Warwick D, Brenkel I. The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study. J Bone Joint Surg Br 2007;89:887-892.

    • Search Google Scholar
    • Export Citation
  • 239

    Dennis M, Sandercock PA, Reid J. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet 2009;373:1958-1965.

    • Search Google Scholar
    • Export Citation
  • 240

    Jaff MR, McMurtry MS, Archer SL. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011;123:1788-1830.

    • Search Google Scholar
    • Export Citation
  • 241

    Comerota AJ, Aldridge SC. Thrombolytic therapy for deep venous thrombosis: a clinical review. Can J Surg 1993;36:359-364.

  • 242

    Mewissen MW, Seabrook GR, Meissner MH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 1999;211:39-49.

    • Search Google Scholar
    • Export Citation
  • 243

    Enden T, Klow NE, Sandvik L. Catheter-directed thrombolysis vs. anticoagulant therapy alone in deep vein thrombosis: results of an open randomized, controlled trial reporting on short-term patency. J Thromb Haemost 2009;7:1268-1275.

    • Search Google Scholar
    • Export Citation
  • 244

    Kim HS, Preece SR, Black JH. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg 2008;47:388-394.

    • Search Google Scholar
    • Export Citation
  • 245

    Dolovich LR, Ginsberg JS, Douketis JD. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000;160:181-188.

    • Search Google Scholar
    • Export Citation
  • 246

    Buller HR, Davidson BL, Decousus H. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003;349:1695-1702.

    • Search Google Scholar
    • Export Citation
  • 247

    Akl EA, Vasireddi SR, Gunukula S. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011;2:CD006649.

    • Search Google Scholar
    • Export Citation
  • 248

    Deitcher SR, Kessler CM, Merli G. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389-396.

    • Search Google Scholar
    • Export Citation
  • 249

    Hull RD, Pineo GF, Mah AF. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium [abstract]. J Thromb Haemost 2003;1(Suppl 1):Abstract OC395.

    • Search Google Scholar
    • Export Citation
  • 250

    Akl EA, Barba M, Rohilla S. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008;2:CD006650.

    • Search Google Scholar
    • Export Citation
  • 251

    Kakkar AK, Levine MN, Kadziola Z. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004;22:1944-1948.

    • Search Google Scholar
    • Export Citation
  • 252

    Lee AY, Rickles FR, Julian JA. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 2005;23:2123-2129.

    • Search Google Scholar
    • Export Citation
  • 253

    Altinbas M, Coskun HS, Er O. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004;2:1266-1271.

    • Search Google Scholar
    • Export Citation
  • 254

    Klerk CP, Smorenburg SM, Otten HM. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005;23:2130-2135.

    • Search Google Scholar
    • Export Citation
  • 255

    Akl EA, van Doormaal FF, Barba M. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res 2008;27:4.

    • Search Google Scholar
    • Export Citation
  • 256

    Kovacs MJ, Kahn SR, Rodger M. A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study). J Thromb Haemost 2007;5:1650-1653.

    • Search Google Scholar
    • Export Citation
  • 257

    Leon L, Giannoukas AD, Dodd D. Clinical significance of superficial vein thrombosis. Eur J Vasc Endovasc Surg 2005;29:10-17.

  • 258

    van Weert H, Dolan G, Wichers I. Spontaneous superficial venous thrombophlebitis: does it increase risk for thromboembolism? A historic follow-up study in primary care. J Fam Pract 2006;55:52-57.

    • Search Google Scholar
    • Export Citation
  • 259

    Marchiori A, Verlato F, Sabbion P. High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized study. Haematologica 2002;87:523-527.

    • Search Google Scholar
    • Export Citation
  • 260

    A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis. Arch Intern Med 2003;163:1657-1663.

    • Search Google Scholar
    • Export Citation
  • 261

    Condat B, Pessione F, Hillaire S. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001;120:490-497.

    • Search Google Scholar
    • Export Citation
  • 262

    Dentali F, Ageno W, Witt D. Natural history of mesenteric venous thrombosis in patients treated with vitamin K antagonists: a multi-centre, retrospective cohort study. Thromb Haemost 2009;102:501-504.

    • Search Google Scholar
    • Export Citation
  • 263

    Hollingshead M, Burke CT, Mauro MA. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol 2005;16:651-661.

    • Search Google Scholar
    • Export Citation
  • 264

    Kim HS, Patra A, Khan J. Transhepatic catheter-directed thrombectomy and thrombolysis of acute superior mesenteric venous thrombosis. J Vasc Interv Radiol 2005;16:1685-1691.

    • Search Google Scholar
    • Export Citation
  • 265

    Sharma S, Texeira A, Texeira P. Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol 2004;40:172-180.

    • Search Google Scholar
    • Export Citation
  • 266

    Smalberg JH, Spaander MV, Jie KS. Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosis. Thromb Haemost 2008;100:1084-1088.

    • Search Google Scholar
    • Export Citation
  • 267

    Garcia-Pagan JC, Heydtmann M, Raffa S. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology 2008;135:808-815.

    • Search Google Scholar
    • Export Citation
  • 268

    Darwish Murad S, Plessier A, Hernandez-Guerra M. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009;151:167-175.

    • Search Google Scholar
    • Export Citation
  • 269

    Eapen CE, Velissaris D, Heydtmann M. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut 2006;55:878-884.

    • Search Google Scholar
    • Export Citation
  • 270

    Mancuso A, Fung K, Mela M. TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol 2003;38:751-754.

  • 271

    Perello A, Garcia-Pagan JC, Gilabert R. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002;35:132-139.

    • Search Google Scholar
    • Export Citation
  • 272

    Rossle M, Olschewski M, Siegerstetter V. The Budd-Chiari syndrome: outcome after treatment with the transjugular intrahepatic portosystemic shunt. Surgery 2004;135:394-403.

    • Search Google Scholar
    • Export Citation
  • 273

    Hemming AW, Langer B, Greig P. Treatment of Budd-Chiari syndrome with portosystemic shunt or liver transplantation. Am J Surg 1996;171:176-180.

    • Search Google Scholar
    • Export Citation
  • 274

    Zeitoun G, Escolano S, Hadengue A. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology 1999;30:84-89.

    • Search Google Scholar
    • Export Citation
  • 275

    Panis Y, Belghiti J, Valla D. Portosystemic shunt in Budd-Chiari syndrome: long-term survival and factors affecting shunt patency in 25 patients in Western countries. Surgery 1994;115:276-281.

    • Search Google Scholar
    • Export Citation
  • 276

    Pisani-Ceretti A, Intra M, Prestipino F. Surgical and radiologic treatment of primary Budd-Chiari syndrome. World J Surg 1998;22:48-53.

  • 277

    Slakey DP, Klein AS, Venbrux AC, Cameron JL. Budd-Chiari syndrome: current management options. Ann Surg 2001;233:522-527.

  • 278

    Darwish Murad S, Valla DC, de Groen PC. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004;39:500-508.

    • Search Google Scholar
    • Export Citation
  • 279

    Perez-Ayuso RM, Valderrama S, Espinoza M. Endoscopic band ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhotic patients with high risk esophageal varices. Ann Hepatol 2010;9:15-22.

    • Search Google Scholar
    • Export Citation
  • 280

    Lay CS, Tsai YT, Lee FY. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol 2006;21:413-419.

    • Search Google Scholar
    • Export Citation
  • 281

    Schepke M, Kleber G, Nurnberg D. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2004;40:65-72.

    • Search Google Scholar
    • Export Citation
  • 282

    Psilopoulos D, Galanis P, Goulas S. Endoscopic variceal ligation vs. propranolol for prevention of first variceal bleeding: a randomized controlled trial. Eur J Gastroenterol Hepatol 2005;17:1111-1117.

    • Search Google Scholar
    • Export Citation
  • 283

    Sarin SK, Wadhawan M, Agarwal SR. Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding. Am J Gastroenterol 2005;100:797-804.

    • Search Google Scholar
    • Export Citation
  • 284

    Sarin SK, Gupta N, Jha SK. Equal efficacy of endoscopic variceal ligation and propranolol in preventing variceal bleeding in patients with noncirrhotic portal hypertension. Gastroenterology 2010;139:1238-1245.

    • Search Google Scholar
    • Export Citation
  • 285

    Funakoshi N, Segalas-Largey F, Duny Y. Benefit of combination beta-blocker and endosco